Edgewise Therapeutics
Edgewise Therapeutics is a biotechnology company focused on developing therapies for muscular dystrophies and cardiac conditions, advancing drugs like EDG-5506 and EDG-7500 through clinical trials.
Services
Edgewise Therapeutics focuses on developing novel muscle-targeted therapies aimed at treating Duchenne, Becker, Limb-Girdle muscular dystrophies, and McArdle disease. They utilize a proprietary drug discovery platform that identifies small molecule precision medicines, which regulate key proteins in muscle tissue. This platform measures integrated muscle function in whole organ extracts, providing a targeted approach to muscle therapy. Their services also include conducting extensive clinical trials to ensure the safety, efficacy, and pharmacokinetics of their developing treatments.
Products
Edgewise Therapeutics is advancing EDG-5506 in clinical development for the treatment of muscular dystrophies. EDG-5506 specifically targets fast skeletal muscle fibers to improve muscle function. Additionally, they are developing EDG-7500, a first-in-class oral selective cardiac sarcomere modulator. EDG-7500 is intended for the treatment of hypertrophic cardiomyopathy and other diseases of cardiac diastolic dysfunction. Both products are currently undergoing clinical trials to evaluate their effectiveness and safety in patient populations.
Clinical Trials
Edgewise Therapeutics is actively conducting clinical trials for both EDG-5506 and EDG-7500. These studies focus on evaluating the safety, efficacy, and pharmacokinetics of these treatments in patients affected by muscular dystrophies and cardiac diastolic dysfunction. Through these trials, the company aims to validate the effectiveness of their therapies and gather critical data needed for regulatory approval and eventual commercialization.
Community Engagement
Edgewise Therapeutics is engaged in educational and advocacy efforts aimed at raising awareness and support for individuals with rare muscle disorders. They achieve this through community newsletters and partnerships with neuromuscular organizations. These initiatives help to disseminate important information, provide support to affected individuals and their families, and foster a stronger community around these rare conditions.